Venetoclax Mechanism Of Action Cll. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Accelerated approval based on overall response rate and duration of response; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. There are no available human data on use in pregnant women; Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Venetoclax has a distinct mechanism of action; Venetoclax derives from science, and it works. Based on its mechanism of action and.
Venetoclax Mechanism Of Action Cll : Based On Its Mechanism Of Action And Findings In Animals, May Cause Embryofetal Harm When Administered.
Venclexta Venetoclax For The Treatment Of Chronic Lymphocytic Leukaemia Clinical Trials Arena. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Accelerated approval based on overall response rate and duration of response; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Venetoclax derives from science, and it works. Venetoclax has a distinct mechanism of action; Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Based on its mechanism of action and. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. There are no available human data on use in pregnant women; Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling.
Obinutuzmab, ibrutinib, and venetoclax in relapsed/refractory chronic lymphocytic leukemia (cll).
A phase i study combining cdk2/9 inhibitor cyc065 with venetoclax, a bcl2 inhibitor, to treat relapsed or refractory chronic lymphocytic leukemia (cll) session name: The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Venetoclax resistance in chronic lymphocytic leukemia. In this whiteboard video, dr. An update on two trials evaluating venetoclax in subsets of cll. The us, eu and australia have approved venetoclax for use in some patients with chronic lymphocytic. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Venetoclax derives from science, and it works. Venetoclax for treating chronic lymphocytic lymphoma (cll). Venclexta (venetoclax tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources. Accelerated approval based on overall response rate and duration of response; In cll upregulation of mcl1 is thought to be an escape mechanism for venetoclax treated cells. It targets bcl2, a protein central to the survival of cll cells. A phase i study combining cdk2/9 inhibitor cyc065 with venetoclax, a bcl2 inhibitor, to treat relapsed or refractory chronic lymphocytic leukemia (cll) session name: Obinutuzmab, ibrutinib, and venetoclax in relapsed/refractory chronic lymphocytic leukemia (cll). Based on the mechanism of action and studies from animal reproduction studies, venetoclax is seemed to cause. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Fda's clinpharm review focused on. There are no available human data on use in pregnant women; What types of cancers can venetoclax treat? © 2019 imedex, an hmp company. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Based on its mechanism of action and. The sponsor and fda both agreed that this increase was desirable. Update on venetoclax for cll. Venetoclax has a distinct mechanism of action;
Venclexta Venetoclax For The Treatment Of Chronic Lymphocytic Leukaemia Clinical Trials Arena - This Review Focuses On Venetoclax, Its Mechanism Of Action, Pharmacology, And Clinical Trial Data Chronic Lymphocytic Leukemia (Cll) Is A Malignancy Of Mature B Lymphocytes That Is Characterized By The Gradual Accumulation Of Cd5+19+23+ B Cells In The Blood, Lymph Nodes, And Bone Marrow.
Double Hit In Chronic Lymphocytic Leukemia Therapeutic Strategies For Patients With 17p Deletion And Tp53 Mutation. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Venetoclax has a distinct mechanism of action; The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Accelerated approval based on overall response rate and duration of response; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. There are no available human data on use in pregnant women; Venetoclax derives from science, and it works. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Based on its mechanism of action and. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling.
Venetoclax Rituximab In Relapsed Or Refractory Chronic Lymphocytic Leukemia Nejm . Venetoclax, Sold Under The Brand Names Venclexta And Venclyxto, Is A Medication Used To Treat Adults With Chronic Lymphocytic Leukemia (Cll), Small Lymphocytic Lymphoma (Sll).
Cll Sll New Therapeutic Strategies For The Practicing Clinician Ppt Download. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Venetoclax derives from science, and it works. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Accelerated approval based on overall response rate and duration of response; Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Venetoclax has a distinct mechanism of action; Based on its mechanism of action and. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow.
Cureus Venetoclax In The Treatment Of Chronic Lymphocytic Leukemia Evidence Expectations And Future Prospects , Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll).
Targeting Bcl2 With Bh3 Mimetics Basic Science And Clinical Application Of Venetoclax In Chronic Lymphocytic Leukemia And Related B Cell Malignancies Roberts 2017 Clinical Pharmacology Amp Therapeutics Wiley Online Library. The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). There are no available human data on use in pregnant women; Accelerated approval based on overall response rate and duration of response; Venetoclax derives from science, and it works. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Venetoclax has a distinct mechanism of action; Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling.
Ibrutinib Imbruvica Treatment For Cll Chemoexperts . Purposethe Treatment Of Chronic Lymphocytic Leukemia (Cll) Has Been Revolutionized By Targeted Therapies That Either Inhibit Proliferation (Ibrutinib) Or Reactivate Apoptosis (Venetoclax).
Btki Improves Disease Control In Cll After Progression On Venetoclax Ash Clinical News. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Venetoclax derives from science, and it works. Accelerated approval based on overall response rate and duration of response; Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Based on its mechanism of action and. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). There are no available human data on use in pregnant women; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Venetoclax has a distinct mechanism of action; Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling.
Venetoclax Venclexta Oncology Nurse Advisor : There Are No Available Human Data On Use In Pregnant Women;
Bertrand Delsuc عÙ٠تÙÙتر Ph1 Ven Obi In Cll Just Out In Blood Not Death But 29 Gr3 4 Infections In R R Pts Phase 1b Study Of Venetoclax Obinutuzumab In Previously Untreated And. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Accelerated approval based on overall response rate and duration of response; Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. There are no available human data on use in pregnant women; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Based on its mechanism of action and. Venetoclax derives from science, and it works. Venetoclax has a distinct mechanism of action;
Venetoclax Rituximab In Relapsed Or Refractory Chronic Lymphocytic Leukemia Nejm - © 2019 Imedex, An Hmp Company.
Btki Improves Disease Control In Cll After Progression On Venetoclax Ash Clinical News. Accelerated approval based on overall response rate and duration of response; Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). There are no available human data on use in pregnant women; Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and. The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Venetoclax has a distinct mechanism of action; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Venetoclax derives from science, and it works.
Full Text Development Of Venetoclax For Therapy Of Lymphoid Malignancies Dddt : Obinutuzmab, Ibrutinib, And Venetoclax In Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll).
9 Stephen Mulligan. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Venetoclax derives from science, and it works. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). There are no available human data on use in pregnant women; Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Accelerated approval based on overall response rate and duration of response; Venetoclax has a distinct mechanism of action; Based on its mechanism of action and. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. The drug venetoclax works by blocking the action of the bcl2 protein, depicted here.
Full Text Obinutuzumab In Chronic Lymphocytic Leukemia Design Development And Dddt - Venclexta (Venetoclax Tablets) May Treat, Side Effects, Dosage, Drug Interactions, Warnings, Patient Labeling, Reviews, And Related Medications Including Drug Comparison And Health Resources.
Treatment Strategies For Relapsed Refractory Cll Ppt Download. The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. There are no available human data on use in pregnant women; Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Accelerated approval based on overall response rate and duration of response; Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. Based on its mechanism of action and. Venetoclax has a distinct mechanism of action; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Venetoclax derives from science, and it works. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women;
Venetoclax Venclexta Obinutuzumab Gazyva For Cll Chemoexperts , The Us, Eu And Australia Have Approved Venetoclax For Use In Some Patients With Chronic Lymphocytic.
9 Stephen Mulligan. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). Venetoclax derives from science, and it works. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Venetoclax has a distinct mechanism of action; This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. There are no available human data on use in pregnant women; The drug venetoclax works by blocking the action of the bcl2 protein, depicted here. Based on its mechanism of action and. Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Accelerated approval based on overall response rate and duration of response; Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma.
Bcl 2 Antagonism To Target The Intrinsic Mitochondrial Pathway Of Apoptosis Clinical Cancer Research - Fda's Clinpharm Review Focused On.
Revolution Of Chronic Lymphocytic Leukemia Therapy The Chemo Free Treatment Paradigm Springerlink. Notch1 mutations in chronic lymphocytic leukemia (cll) lead to accumulation of notch1 intracellular domain (nicd) and prolong signaling. Indicated for patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). There are no available human data on use in pregnant women; Clarity is a phase ii trial that combined ibrutinib with venetoclax in patients with relapsed or refractory cll. This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data chronic lymphocytic leukemia (cll) is a malignancy of mature b lymphocytes that is characterized by the gradual accumulation of cd5+19+23+ b cells in the blood, lymph nodes, and bone marrow. Venetoclax derives from science, and it works. Venetoclax, sold under the brand names venclexta and venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll). Based on its mechanism of action and. Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered. Fda approves venetoclax (venclexta) plus obinutuzumab (gazyva) for the initial treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma. Venetoclax has a distinct mechanism of action; Purposethe treatment of chronic lymphocytic leukemia (cll) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Indicated for patients with cll with 17p deletion, as detected there are no available human data on use in pregnant women; Accelerated approval based on overall response rate and duration of response; The drug venetoclax works by blocking the action of the bcl2 protein, depicted here.